Antibacterial Envelope Stabilizes Implantable Cardiac Devices
By HospiMedica International staff writers Posted on 06 Oct 2014 |
An innovative absorbable mesh envelope covers an implantable cardiac device to help stabilize it after implantation and reduce surgical-site infections.
The TYRX absorbable antibacterial envelope is intended for cardiac implantable electronic devices (CIEDs) such as a pacemaker, an implantable cardioverter defibrillator (ICD), or a cardiac resynchronization therapy (CRT) device. The envelope first stabilizes the CIED, then releases rifampin and minocycline to the surgical site to prevent infection, and finally dissolves and is fully absorbed approximately nine weeks after implantation.
In studies of the efficacy of the previous, non-absorbable TYRX antibacterial envelope, six-month follow-up data showed that patients who received an ICD or CRT replacement device with a TYRX antibacterial envelope experienced low infection rates of 0.2%, compared to 1.9% of patients who did not receive the envelope. The rate of device mechanical complications was also low (4%) in patients who received the envelope. The TYRX absorbable antibacterial envelope is a product of Medtronic (Minneapolis, MN, USA), and has received the European Community CE marking of approval.
“While the risk of infection is low for most patients receiving an implantable device, the TYRX envelope offers an extra layer of protection,” said John Liddicoat, MD, president of the cardiac rhythm and heart failure business and senior vice president of Medtronic. “The TYRX envelope provides physicians with a proven solution to make implantable device procedures safer for their patients.”
“The TYRX envelope seems to offer physicians a simple, yet highly effective method of reducing surgical-site infections, particularly among those high-risk patients who are undergoing a repeat procedure,” said Charles Kennergren, MD, PhD, of Sahlgrenska University Hospital (Gothenburg, Sweden), who performed the first implant of the envelope in Europe. “We have high expectations for this novel product, both in terms of reducing infection rates as well as avoiding device migrations.”
Minocycline and rifampin have been shown to provide a broad spectrum of activity against both antibiotic-sensitive and antibiotic-resistant bacteria, with the combination superior to vancomycin, clindamycin, novobiocin, or minocycline alone. In combination, they have been found to be more potent than a combination of chlorhexidine and silver sulfadiazine, and equivalent to ceftazidime or amphotericin B against gram negative bacilli and Candida albicans.
Related Links:
Medtronic
The TYRX absorbable antibacterial envelope is intended for cardiac implantable electronic devices (CIEDs) such as a pacemaker, an implantable cardioverter defibrillator (ICD), or a cardiac resynchronization therapy (CRT) device. The envelope first stabilizes the CIED, then releases rifampin and minocycline to the surgical site to prevent infection, and finally dissolves and is fully absorbed approximately nine weeks after implantation.
In studies of the efficacy of the previous, non-absorbable TYRX antibacterial envelope, six-month follow-up data showed that patients who received an ICD or CRT replacement device with a TYRX antibacterial envelope experienced low infection rates of 0.2%, compared to 1.9% of patients who did not receive the envelope. The rate of device mechanical complications was also low (4%) in patients who received the envelope. The TYRX absorbable antibacterial envelope is a product of Medtronic (Minneapolis, MN, USA), and has received the European Community CE marking of approval.
“While the risk of infection is low for most patients receiving an implantable device, the TYRX envelope offers an extra layer of protection,” said John Liddicoat, MD, president of the cardiac rhythm and heart failure business and senior vice president of Medtronic. “The TYRX envelope provides physicians with a proven solution to make implantable device procedures safer for their patients.”
“The TYRX envelope seems to offer physicians a simple, yet highly effective method of reducing surgical-site infections, particularly among those high-risk patients who are undergoing a repeat procedure,” said Charles Kennergren, MD, PhD, of Sahlgrenska University Hospital (Gothenburg, Sweden), who performed the first implant of the envelope in Europe. “We have high expectations for this novel product, both in terms of reducing infection rates as well as avoiding device migrations.”
Minocycline and rifampin have been shown to provide a broad spectrum of activity against both antibiotic-sensitive and antibiotic-resistant bacteria, with the combination superior to vancomycin, clindamycin, novobiocin, or minocycline alone. In combination, they have been found to be more potent than a combination of chlorhexidine and silver sulfadiazine, and equivalent to ceftazidime or amphotericin B against gram negative bacilli and Candida albicans.
Related Links:
Medtronic
Read the full article by registering today, it's FREE!
Register now for FREE to HospiMedica.com and get complete access to news and events that shape the world of Hospital Medicine.
- Free digital version edition of HospiMedica International sent by email on regular basis
- Free print version of HospiMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of HospiMedica International in digital format
- Free HospiMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Surgical Techniques News
- Miniaturized Ultrasonic Scalpel Enables Faster and Safer Robotic-Assisted Surgery
- AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy Detects More Lesions
- First-Ever Contact Force Pulsed Field Ablation System to Transform Treatment of Ventricular Arrhythmias
- Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends
- Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries
- Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant
- Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment
- World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets
- Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography
- AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time
- Cutting-Edge Robotic Bronchial Endoscopic System Provides Prompt Intervention during Emergencies
- Handheld Device for Fluorescence-Guided Surgery a Game Changer for Removal of High-Grade Glioma Brain Tumors
- Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing
- Novel Rigid Endoscope System Enables Deep Tissue Imaging During Surgery
- Robotic Nerve ‘Cuffs’ Could Treat Various Neurological Conditions
- Flexible Microdisplay Visualizes Brain Activity in Real-Time To Guide Neurosurgeons